<p>Pfizer is raising its revenue expectations for the year with a huge roll out of its COVID-19 vaccine as well as strong performances from other parts of its business. </p>
<p>The company reported first-quarter earnings of $4.88 billion, or 86 cents per share. Per-share earnings were 93 cents if one-time costs or gains are removed. That far above the 79 cents Wall Street was looking for, according to a survey by Zacks Investment Research.</p>
<p>Revenue was $14.58 billion, also easily exceeding forecasts of $13.49 billion from industry analysts. </p>
<p>Pfizer expects full-year earnings in the range of $3.55 to $3.65 per share, with revenue in the range of $70.5 billion to $72.5 billion.</p>
<p>The New York company is manufacturing hundreds of millions of doses of the COVID-19 shot and pushing forward on research gauging its effectiveness in different patient groups, such as teens and people with compromised immune systems.</p>
<p>Pfizer has said that this year it can produce 2 billion doses of the vaccine, developed with its German partner BioNTech, including 200 million doses promised for the U.S. by the end of May.</p>
<p>_____</p>
<p>Portions of this story was generated by Automated Insights (<a href="http://automatedinsights.com/ap">http://automatedinsights.com/ap</a>) using data from Zacks Investment Research. Access a Zacks stock report on PFE at <a href="https://www.zacks.com/ap/PFE">https://www.zacks.com/ap/PFE</a></p>
